FI3390448T3 - Intravesikaalinen hoito virtsarakon syöpää varten - Google Patents

Intravesikaalinen hoito virtsarakon syöpää varten Download PDF

Info

Publication number
FI3390448T3
FI3390448T3 FIEP16819062.7T FI16819062T FI3390448T3 FI 3390448 T3 FI3390448 T3 FI 3390448T3 FI 16819062 T FI16819062 T FI 16819062T FI 3390448 T3 FI3390448 T3 FI 3390448T3
Authority
FI
Finland
Prior art keywords
composition
antibodies
use according
bladder
treatment method
Prior art date
Application number
FIEP16819062.7T
Other languages
English (en)
Finnish (fi)
Inventor
Kjetil Hestdal
Original Assignee
Photocure Asa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Photocure Asa filed Critical Photocure Asa
Application granted granted Critical
Publication of FI3390448T3 publication Critical patent/FI3390448T3/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0061—5-aminolevulinic acid-based PDT: 5-ALA-PDT involving porphyrins or precursors of protoporphyrins generated in vivo from 5-ALA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
FIEP16819062.7T 2015-12-17 2016-12-19 Intravesikaalinen hoito virtsarakon syöpää varten FI3390448T3 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1522311.8A GB201522311D0 (en) 2015-12-17 2015-12-17 Use
PCT/EP2016/081798 WO2017103280A1 (en) 2015-12-17 2016-12-19 Intravesical therapy for bladder cancer

Publications (1)

Publication Number Publication Date
FI3390448T3 true FI3390448T3 (fi) 2024-07-10

Family

ID=55311161

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP16819062.7T FI3390448T3 (fi) 2015-12-17 2016-12-19 Intravesikaalinen hoito virtsarakon syöpää varten

Country Status (13)

Country Link
US (2) US20180371101A1 (enExample)
EP (1) EP3390448B1 (enExample)
JP (1) JP2018538308A (enExample)
KR (1) KR102878726B1 (enExample)
CN (1) CN108699147B (enExample)
AU (1) AU2016372570B2 (enExample)
BR (1) BR112018012116A2 (enExample)
DK (1) DK3390448T3 (enExample)
ES (1) ES2981986T3 (enExample)
FI (1) FI3390448T3 (enExample)
GB (1) GB201522311D0 (enExample)
PL (1) PL3390448T3 (enExample)
WO (1) WO2017103280A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA48579A (fr) 2015-09-01 2020-03-18 Agenus Inc Anticorps anti-pd1 et méthodes d'utilisation de ceux-ci
GB201522311D0 (en) * 2015-12-17 2016-02-03 Photocure Asa Use
AU2017373945B2 (en) 2016-12-07 2025-01-23 Agenus Inc. Antibodies and methods of use thereof
CA3079496C (en) * 2017-12-01 2021-06-01 Sbi Pharmaceuticals Co., Ltd. Pharmaceutical composition for enhancing antitumor effect by immune checkpoint inhibitor
WO2024184417A1 (en) 2023-03-07 2024-09-12 Photocure Asa Therapy for bladder cancer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2157424T3 (es) 1995-03-10 2001-08-16 Photocure Asa Esteres de acido 5-aminolevulinico como agentes fotosensibilizantes en fotoquimioterapia.
ATE481985T1 (de) 2002-07-03 2010-10-15 Ono Pharmaceutical Co Immunpotenzierende zusammensetzungen
GB0406917D0 (en) 2004-03-26 2004-04-28 Photocure Asa Compounds
CN104945508B (zh) 2007-06-18 2019-02-22 默沙东有限责任公司 针对人程序性死亡受体pd-1的抗体
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
EP3133086B1 (en) * 2008-09-26 2018-08-01 Dana-Farber Cancer Institute, Inc. Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses thereof
CA3120172A1 (en) 2008-12-09 2010-07-08 Genentech, Inc. Anti-pd-l1 antibodies and their use to enhance t-cell function
TWI835048B (zh) 2011-08-01 2024-03-11 美商建南德克公司 利用pd-1軸結合拮抗劑及mek抑制劑治療癌症之方法
MX349096B (es) 2011-11-28 2017-07-11 Merck Patent Gmbh Anticuerpos anti-pd-l1 y sus usos.
SG10201603055WA (en) 2012-05-31 2016-05-30 Genentech Inc Methods Of Treating Cancer Using PD-L1 Axis Binding Antagonists And VEGF Antagonists
CN108135934B (zh) * 2015-10-19 2024-09-10 永恒生物科技股份有限公司 通过组合疗法治疗实体或淋巴肿瘤的方法
GB201522309D0 (en) * 2015-12-17 2016-02-03 Photocure Asa Use
GB201522311D0 (en) * 2015-12-17 2016-02-03 Photocure Asa Use

Also Published As

Publication number Publication date
RU2018124866A (ru) 2020-01-17
WO2017103280A1 (en) 2017-06-22
GB201522311D0 (en) 2016-02-03
KR102878726B1 (ko) 2025-10-29
ES2981986T3 (es) 2024-10-14
EP3390448B1 (en) 2024-06-05
CN108699147A (zh) 2018-10-23
KR20180094988A (ko) 2018-08-24
BR112018012116A2 (en) 2018-12-04
RU2018124866A3 (enExample) 2020-02-26
PL3390448T3 (pl) 2024-09-16
US20180371101A1 (en) 2018-12-27
JP2018538308A (ja) 2018-12-27
AU2016372570A1 (en) 2018-07-12
CN108699147B (zh) 2022-11-01
US20190241672A1 (en) 2019-08-08
DK3390448T3 (da) 2024-07-22
EP3390448A1 (en) 2018-10-24
AU2016372570B2 (en) 2024-01-18
US11066478B2 (en) 2021-07-20
CA3008548A1 (en) 2017-06-22
WO2017103280A9 (en) 2017-11-09

Similar Documents

Publication Publication Date Title
FI3390448T3 (fi) Intravesikaalinen hoito virtsarakon syöpää varten
CO6351803A2 (es) Anticuerpos monoclonales contra el inhibidor de la via del factor tisular (tfpi)
NZ723369A (en) Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema
RU2019112029A (ru) Применение комбинации антитела к pd-1 и ингибитора vegfr в изготовлении лекарственного средства для лечения злокачественных новообразований
EA201792541A3 (ru) Ингибиторы рециркуляции желчных кислот для лечения гиперхолемии и холестатического заболевания печени
EA201991704A3 (ru) Моноклональные антитела против ингибитора пути тканевого фактора (tfpi)
EA201500373A1 (ru) Маситиниб или его соль для лечения рака, фармацевтическая композиция, лекарственное средство и набор
FI3728313T3 (fi) Syövän yhdistelmähoito IAP-antagonistilla ja anti-PD-1-molekyylillä
EA202091514A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ РАКА ТОЛСТОЙ КИШКИ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ НАНОЧАСТИЦАМИ С ИНГИБИТОРОМ mTOR
JP2018538308A5 (enExample)
RU2015104001A (ru) Комбинированная терапия для лечения глиобластомы
AR095197A1 (es) Combinación de un inhibidor de egfr t790m y un inhibidor de egfr para el tratamiento del cáncer pulmonar de células no pequeñas
FI3463436T3 (fi) Rokote yhdistelmänä immuunivasteen tarkastuspisteen estäjän kanssa käytettäväksi hoidettaessa syöpää
JP2020502198A5 (enExample)
RU2014139955A (ru) Прокаспазная комбинированная терапия при глиобластоме
JP2017519006A5 (enExample)
EA202290024A1 (ru) Способы лечения болезни фабри у пациентов с почечной недостаточностью
FI3389717T3 (fi) Neoadjuvanttihoito virtsarakon syöpää varten
WO2020132560A3 (en) Compositions and methods for cancer therapy
PE20221768A1 (es) Inhibidores de egfr
IL320024A (en) Perk inhibitor hc-5404 in combination with anti-pd-1 antibody and/or an antiangiogenetic agent for use in the treatment of cancer
EA201491870A1 (ru) Способ лечения гиперурикемии у больных подагрой с помощью галофената или галофеновой кислоты и противовоспалительного агента
FI3646869T3 (fi) Solunsalpaajahoito atsabisykloyhdisteellä syövän hoitamiseksi
BR112022007349A2 (pt) Homodímero de quinureninase, método para produzir um homodímero de quinureninase peguilado, formulação farmacêutica e método para tratar um sujeito tendo um tumor
PL425038A1 (pl) Nowe peptydowe pochodne płytkopochodnego czynnika wzrostu (PDGF), sposób ich otrzymywania, kompozycja farmaceutyczna oraz zastosowanie